Brotizolam

This classification denotes a benzodiazepine with the molecular formula C15H10BrClN4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XZM1R3DKF, chemically known as 8-bromo-6-(o-chlorophenyl)-1-methyl-4h-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine but generally known as brotizolam, which bears US NIH Compound Identifier 2451. European Medicines Agency schedules Brotizolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05933MIG. The term BROTIZOLAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, No. 10 1979, List 19). World Health Organization schedules brotizolam in its Anatomical Therapeutic Chemical (ATC) Classification. BROTIZOLAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brotizolam under HS 29349100 and SITC 51579. As of Q4 2014, BROTIZOLAM remains the US FDA Preferred Term for this commodity. Brotizolam bears US NLM identifiers UMLS ID C0054151 and NCI Concept Code C87057. SMILES: BRC1SC2N3C(NNC3C)CN=C(C2C1)C1C(CL)CCCC1.